Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Sheds Hycor Biomedical Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Private equity firm Linden LLC has paid an undisclosed sum to purchase the Hycor Biomedical business of Agilent Technologies.

Hycor, which specializes in allergy, autoimmune, and urinalysis diagnostics, became part of Agilent through that firm's 2007 acquisition of Stratagene. Hycor had only been part of Stratagene for a few years before the deal with Agilent.

"We believe Hycor has great opportunities outside of the Agilent portfolio," Nick Roelofs, president of Agilent's Life Sciences Group, said in a statement. ""Hycor is an innovative, profitable and growing business, but it does not fit the core focus of our life science business."

Agilent officials declined to provide revenue figures for the Hycor business.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.